NervGen Pharma Stock (NASDAQ:NGEN)

Financials Chart

Previous Close

$3.73

52W Range

$1.50 - $6.30

50D Avg

$4.19

200D Avg

$3.40

Market Cap

$298.63M

Avg Vol (3M)

$141.75K

Beta

0.98

Div Yield

-

NGEN Company Profile

NervGen Pharma Corp. is a clinical-stage biotechnology company developing therapies aimed at treating nerve damage and neurodegenerative conditions by targeting mechanisms that inhibit nervous system repair.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

-

IPO Date

Feb 08, 2021

Website

NGEN Performance

NGEN Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-17.33M	$-13.41M	$-16.99M
Net Income	$-16.68M	$-16.89M	$-15.29M
EBITDA	$-16.62M	$-16.78M	$-14.82M
Basic EPS	$-0.25	$-0.28	$-0.29
Diluted EPS	$-0.25	$-0.28	$-0.29

Fiscal year ends in Dec 24 | Currency in USD